TLDR
- Cigna reported Q1 EPS of $7.79, beating the $7.60 consensus estimate
- Revenue rose 5% year-over-year to $68.5 billion, topping the $66.3 billion estimate
- Full-year 2026 EPS guidance raised to at least $30.35, up $0.10 from prior guidance
- Stock fell around 3% despite the beat, with pharmacy benefits flagged as a weak spot
- CEO David Cordani retiring July 1; COO Brian Evanko takes over
Cigna posted a solid first quarter but the market wasn’t impressed. The health insurer beat on both earnings and revenue, lifted its full-year outlook, and still watched its stock drop.
CIGNA $CI Q1’26 EARNINGS HIGHLIGHTS
🔹 Adj. Revenue: $68.52B (Est. $66.24B) 🟢; +5% y/y
🔹 Adj. Operating EPS: $7.79 (Est. $7.61) 🟢
🔹 Healthcare Adj. Revenue: $11.48B (Est. $11.37B) 🟢
🔹 Healthcare Medical Care Ratio: 79.8% (Est. 81.0%) 🟢
🔹 FY Adj. Operating EPS Guide: At…— Wall St Engine (@wallstengine) April 30, 2026
Q1 adjusted EPS came in at $7.79, up from $6.74 a year ago and above the Wall Street consensus of $7.60. Revenue hit $68.5 billion, a 5% increase year-over-year, clearing the $66.3 billion estimate.
The company also nudged its full-year 2026 EPS guidance up to at least $30.35, a $0.10 increase from its previous forecast. That midpoint sits just ahead of the analyst consensus of $30.33.
Despite the numbers, the stock fell roughly 3% to around $283 in early trading.
Adjusted income from operations rose 12% to $2.1 billion, compared to $1.8 billion in Q1 2025. The gains were driven by Cigna Healthcare and Evernorth Health Services.
Cigna Healthcare’s pre-tax adjusted income from operations jumped 18% to $1.5 billion. Its medical care ratio improved to 79.8%, down from 82.2% in the year-ago quarter.
Evernorth reported adjusted revenues of $58.4 billion, up 9% year-over-year. Specialty and Care Services income climbed 20% to $1.1 billion.
Pharmacy Business Under the Microscope
The weak link was the pharmacy benefit manager side. TD Cowen’s Charles Rhyee called it the “only blemish” in an otherwise clean report, but noted it wasn’t a surprise given similar weakness at UnitedHealth and Elevance Health. He kept a Buy rating with a $338 price target.
Leerink Partners’ Whit Mayo held a Market Perform, writing that results “look fine” but that “not much jumps off the page as particularly surprising.”
Cigna has been reshaping its PBM business since last fall, moving toward a “rebate-free” model in response to regulatory pressure and public criticism over drug pricing practices.
Leadership Transition Adds Uncertainty
In February, Cigna’s Express Scripts became the first of the three major PBMs to settle with the Federal Trade Commission over insulin pricing litigation. No liability was admitted, and the settlement aligned with the rebate-free model already announced.
Cigna is also heading into a leadership change. CEO David Cordani is retiring on July 1, with COO Brian Evanko stepping in as his replacement.
The combination of a business model transition, a CEO handoff, and a cautious analyst reaction helps explain why a beat-and-raise quarter still wasn’t enough to move the stock higher.
Cigna’s medical care ratio improvement and the organic growth in specialty businesses were the clearest positives from the quarter.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
